FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282928546> ?p ?o ?g. }

• W4282928546 endingPage "89" @default.
• W4282928546 startingPage "82" @default.
• W4282928546 abstract "<b>Rationale: </b> Tumor visualization with near-infrared fluorescence (NIRF) imaging could aid exploration and resection of pancreatic cancer by visualizing the tumor in real time. Conjugation of the near-infrared fluorophore IRDye800CW to the monoclonal antibody bevacizumab enables targeting of vascular endothelial growth factor-A (VEGF-A). The aim of this study was to determine if intraoperative tumor-specific imaging of pancreatic cancer with the fluorescent tracer bevacizumab-800CW is feasible and safe. <b>Materials and Methods:</b> In this multicenter, dose escalation phase I trial patients with suspicion of pancreatic ductal adenocarcinoma (PDAC) were administered bevacizumab-800CW (4.5mg, 10mg or 25mg) three days before surgery. Safety monitoring encompassed allergic or anaphylactic reactions and serious adverse events attributed to bevacizumab-800CW. Intraoperative NIRF imaging was performed immediately after laparotomy, just before and after resection of the specimen. Postoperatively, fluorescence signals on the axial slices and formalin-fixed paraffin-embedded tissue blocks from the resected specimens were correlated to histology. Subsequently, tumor-to-background ratios (TBR) were calculated. <b>Results:</b> Ten patients with clinically suspected PDAC were enrolled in the study. Four of the resected specimens were confirmed PDACs; other malignancies were distal cholangiocarcinoma, ampullary carcinoma and neuroendocrine tumors. No serious adverse events were related to bevacizumab-800CW. In vivo tumor visualization with NIRF imaging differed per tumor type and was non-conclusive. Ex vivo TBRs were 1.3, 1.5 and 2.5 for 4.5mg, 10mg and 25mg groups, respectively. <b>Conclusion:</b> NIRF guided surgery in patients with suspect PDAC using bevacizumab-IRDye800CW is feasible and safe. However, suboptimal TBRs were obtained because no clear distinction between pancreatic cancer from normal or inflamed pancreatic tissue was achieved. Therefore, a more tumor-specific tracer other than bevacizumab-IRDye800CW for PDAC is preferred." @default.
• W4282928546 created "2022-06-16" @default.
• W4282928546 creator A5028689548 @default.
• W4282928546 creator A5034141408 @default.
• W4282928546 creator A5039013764 @default.
• W4282928546 creator A5039637417 @default.
• W4282928546 creator A5039905166 @default.
• W4282928546 creator A5046096257 @default.
• W4282928546 creator A5046229997 @default.
• W4282928546 creator A5049663351 @default.
• W4282928546 creator A5052876669 @default.
• W4282928546 creator A5053643830 @default.
• W4282928546 creator A5070367929 @default.
• W4282928546 creator A5081764473 @default.
• W4282928546 date "2022-06-09" @default.
• W4282928546 modified "2023-10-11" @default.
• W4282928546 title "Intraoperative Molecular Fluorescence Imaging of Pancreatic Cancer by Targeting Vascular Endothelial Growth Factor: A Multicenter Feasibility Dose-Escalation Study" @default.
• W4282928546 cites W159146637 @default.
• W4282928546 cites W1997855844 @default.
• W4282928546 cites W2007429443 @default.
• W4282928546 cites W2012063336 @default.
• W4282928546 cites W2024969564 @default.
• W4282928546 cites W2026762108 @default.
• W4282928546 cites W2028187795 @default.
• W4282928546 cites W2048038826 @default.
• W4282928546 cites W2051543380 @default.
• W4282928546 cites W2055687876 @default.
• W4282928546 cites W2076408358 @default.
• W4282928546 cites W2079652003 @default.
• W4282928546 cites W2106235642 @default.
• W4282928546 cites W2112579958 @default.
• W4282928546 cites W2153996356 @default.
• W4282928546 cites W2343026925 @default.
• W4282928546 cites W2387690073 @default.
• W4282928546 cites W2519930924 @default.
• W4282928546 cites W2554295594 @default.
• W4282928546 cites W2563665409 @default.
• W4282928546 cites W2589907317 @default.
• W4282928546 cites W2765253206 @default.
• W4282928546 cites W2766863587 @default.
• W4282928546 cites W2788340667 @default.
• W4282928546 cites W2802371551 @default.
• W4282928546 cites W2883584659 @default.
• W4282928546 cites W2892272665 @default.
• W4282928546 cites W3024949407 @default.
• W4282928546 doi "https://doi.org/10.2967/jnumed.121.263773" @default.
• W4282928546 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35680414" @default.
• W4282928546 hasPublicationYear "2022" @default.
• W4282928546 type Work @default.
• W4282928546 citedByCount "4" @default.
• W4282928546 countsByYear W42829285462023 @default.
• W4282928546 crossrefType "journal-article" @default.
• W4282928546 hasAuthorship W4282928546A5028689548 @default.
• W4282928546 hasAuthorship W4282928546A5034141408 @default.
• W4282928546 hasAuthorship W4282928546A5039013764 @default.
• W4282928546 hasAuthorship W4282928546A5039637417 @default.
• W4282928546 hasAuthorship W4282928546A5039905166 @default.
• W4282928546 hasAuthorship W4282928546A5046096257 @default.
• W4282928546 hasAuthorship W4282928546A5046229997 @default.
• W4282928546 hasAuthorship W4282928546A5049663351 @default.
• W4282928546 hasAuthorship W4282928546A5052876669 @default.
• W4282928546 hasAuthorship W4282928546A5053643830 @default.
• W4282928546 hasAuthorship W4282928546A5070367929 @default.
• W4282928546 hasAuthorship W4282928546A5081764473 @default.
• W4282928546 hasBestOaLocation W42829285461 @default.
• W4282928546 hasConcept C121608353 @default.
• W4282928546 hasConcept C126322002 @default.
• W4282928546 hasConcept C126838900 @default.
• W4282928546 hasConcept C142724271 @default.
• W4282928546 hasConcept C167734588 @default.
• W4282928546 hasConcept C2776694085 @default.
• W4282928546 hasConcept C2777025900 @default.
• W4282928546 hasConcept C2777802072 @default.
• W4282928546 hasConcept C2777996000 @default.
• W4282928546 hasConcept C2780210213 @default.
• W4282928546 hasConcept C71924100 @default.
• W4282928546 hasConceptScore W4282928546C121608353 @default.
• W4282928546 hasConceptScore W4282928546C126322002 @default.
• W4282928546 hasConceptScore W4282928546C126838900 @default.
• W4282928546 hasConceptScore W4282928546C142724271 @default.
• W4282928546 hasConceptScore W4282928546C167734588 @default.
• W4282928546 hasConceptScore W4282928546C2776694085 @default.
• W4282928546 hasConceptScore W4282928546C2777025900 @default.
• W4282928546 hasConceptScore W4282928546C2777802072 @default.
• W4282928546 hasConceptScore W4282928546C2777996000 @default.
• W4282928546 hasConceptScore W4282928546C2780210213 @default.
• W4282928546 hasConceptScore W4282928546C71924100 @default.
• W4282928546 hasIssue "1" @default.
• W4282928546 hasLocation W42829285461 @default.
• W4282928546 hasLocation W42829285462 @default.
• W4282928546 hasLocation W42829285463 @default.
• W4282928546 hasLocation W42829285464 @default.
• W4282928546 hasLocation W42829285465 @default.
• W4282928546 hasOpenAccess W4282928546 @default.
• W4282928546 hasPrimaryLocation W42829285461 @default.
• W4282928546 hasRelatedWork W2000289892 @default.
• W4282928546 hasRelatedWork W2099929992 @default.
• W4282928546 hasRelatedWork W2123769936 @default.

• next